Literature DB >> 1827434

A phase II study of menogaril in low-grade non-Hodgkin's lymphoma. An NCI Canada Clinical Trials Group study.

J Skillings1, C Cripps, E Eisenhauer, J Pater, S Verma, D Walde.   

Abstract

The NCI Canada Clinical Trials Group conducted a phase II study of menogaril given intravenously every 4 weeks in low-grade non-Hodgkin's lymphoma. Fifteen of 26 eligible patients had had no prior therapy. Partial responses were seen in 9 patients (35%). Toxicity was moderate including myelosuppression, nausea, phlebitis, alopecia, and lethargy. This drug has only modest activity in this potentially responsive group of patients.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1827434     DOI： 10.1007/bf00194551

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  8 in total

1.  Follicular lymphoma; a re-evaluation of its position in the scheme of malignant lymphoma, based on a survey of 253 cases.

Authors:  E B HICKS; H RAPPAPORT; W J WINTER
Journal:  Cancer       Date:  1956 Jul-Aug       Impact factor: 6.860

2.  No initial therapy for stage III and IV non-Hodgkin's lymphomas of favorable histologic types.

Authors:  C S Portlock; S A Rosenberg
Journal:  Ann Intern Med       Date:  1979-01       Impact factor: 25.391

Review 3.  "Good risk" non-Hodgkin lymphomas: approaches to management.

Authors:  C S Portlock
Journal:  Semin Hematol       Date:  1983-01       Impact factor: 3.851

4.  Comparison of combined and single-agent chemotherapy in non-Hodgkin's lymphoma of favourable histological type.

Authors:  T A Lister; M H Cullen; M E Beard; R L Brearley; J M Whitehouse; P F Wrigley; A G Stansfeld; S B Sutcliffe; J S Malpas; D Crowther
Journal:  Br Med J       Date:  1978-03-04

5.  Comparative biological and biochemical effects of nogalamycin and its analogs on L1210 leukemia.

Authors:  L H Li; S L Kuentzel; L L Murch; L M Pschigoda; W C Krueger
Journal:  Cancer Res       Date:  1979-12       Impact factor: 12.701

6.  Histological transformation of non-Hodgkin's lymphoma: a prospective study.

Authors:  M H Cullen; T A Lister; R I Brearley; W S Shand; A G Stansfeld
Journal:  Cancer       Date:  1979-08       Impact factor: 6.860

7.  Non-Hodgkin's lymphoma: a study of the evolution of the disease based upon 92 autopsied cases.

Authors:  R Risdall; R T Hoppe; R Warnke
Journal:  Cancer       Date:  1979-08       Impact factor: 6.860

8.  Phase I study of intravenous menogaril administered intermittently.

Authors:  P Dodion; C Sessa; R Joss; N Crespeigne; Y Willems; M Kitt; J Abrams; C Finet; J E Brewer; W J Adams
Journal:  J Clin Oncol       Date:  1986-05       Impact factor: 44.544
  8 in total
  3 in total

1.  Phase II trial of menogaril in non-Hodgkin's lymphomas: a Southwest Oncology Group trial.

Authors:  D F Moore; T D Brown; M LeBlanc; S Dahlberg; T P Miller; S McClure; R I Fisher
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

2.  Menogaril in the treatment of relapsed multiple myeloma. A phase II trial of the Cancer Center of Wake Forest University.

Authors:  J M Cruz; L D Case; H B Dalton; W L Ramseur; F Richards; D V Jackson; H B Muss; P J Zekan; R A Brodkin; R C Brown
Journal:  Invest New Drugs       Date:  1992-04       Impact factor: 3.850

3.  Phase I clinical and pharmacokinetic study of menogaril (7-con-O-methylnogarol) in previously treated patients with acute leukemia.

Authors:  C Mazurek; J P Dutcher; E L Schwartz; S Garl; L Benson; P H Wiernik
Journal:  Invest New Drugs       Date:  1993-11       Impact factor: 3.850
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.